Table 1.
CCL2 | CCL3 | CCL4 | CCL5 | CCL12 | CXCL1 | CXCL2 | CXCL9 | CXCL10 | CXCL13 | |
---|---|---|---|---|---|---|---|---|---|---|
Coordinate | C5 | C8 | C9 | C11 | C6 | C3 | C10 | C14 | C1 | A1 |
MRcko | ||||||||||
mdx 4WK QUAD | ↓29% | ↓80% | ↑4.9× | ↓5% | ↓47% | ↑1.9× | N.D. | ↑2.0× | ↑3.6× | ↓9% |
mdx 4WK DIA | ↓11% | ↓65% | ↓52% | ↓72% | ↓20% | ↓15% | ↓66% | ↓53% | ↓30% | ↓18% |
WT AID4 TA | === | ↓54% | N.D. | ↓18% | ↓9% | ↓87% | N.D. | ↓14% | N.D. | ↓14% |
Quantification of relative chemokine levels detected in myeloid mineralocorticoid receptor knockout (MRcko) mdx and injured MRcko wild-type (WT) skeletal muscle by pixel densitometry. Results are displayed as fold increases and % decreases in MRcko skeletal muscle relative to the appropriate Cre− controls. Coordinates listed in the table correspond to the individual chemokine’s location (in duplicate) on the immunoblot. Some quantified chemokines were equivalent (===) or not detected (N.D.) compared with Cre− controls. AID4, 4 days after acute injury; DIA, diaphragm; QUAD, quadriceps; TA, tibialis anterior; 4WK, 4 wk of age.